
Dee X said:I think the only person who would have the best chance to most accurately track the source of a peptide is Jano due to the sheer volume of testing they do.
They don't test for TFA or HCI. Only for the peptide itself. I'm not certain they can, or have the ability, to test for TFA.
I was under the impression that nearly all peptides start out with TFA as it is required to cleave the peptides off the solid-phase resin. But maybe they can use HCI for the same process.
I've heard the acetate form is the most desirable, but results in lower purity than other forms. So if you're seeing 99 percent purity, likely not acetate form.
The question I want to know and get a better handle on, is how much TFA is actually present in each dose and does it pose any short or long-term health risks? USP limit is 0.05 percent TFA presence.
Very little data exists on this. You can find studies based on inhaled anesthetics that convert to TFA in the body and cause liver damage. But I'd swagger that TFA amounts in this case are significantly greater than what we might be exposed to.
Best I can do is "anecdotal" evidence that the TFAs present don't cause any short-term health risks. And Janoshik is quoted as saying TFAs presence in these meds is "absolutely inconsequential" when speaking to in vitro use of these peps.